Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org. CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."

Fixed-duration ven after cBTKi progression in CLL @bloodjournals.hematology.org - 79 pts, 71% VR, 82% 2/3L, 20% TP53mut - ORR 78% (CR 41%) - 18-mo PFS 79%, TTNT 80%, OS 84% - VR subgroup: 18-mo PFS 78%, OS 87% - VO subgroup too small Good RW data to support tx sequencing. #oncsky #medsky

Congratulations to Ajay Major, MD, MBA, who is the lead author on a new publication from The Oncologist! Read Now: tinyurl.com/3src42t6 #ACCORDSIntegration #HealthServicesResearch #CancerResearch

TME may explain pola-R-CHP benefit in DLBCL #lymsm - post-hoc RNAseq analysis across 3 RCTs: >1200 pts - low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP - in M1-low pts, pola-R-CHP improved PFS v R-CHOP: HR 0.59 1/2

Huge thank you to @cucancercenter.bsky.social for featuring our latest publication on patient-reported time toxicity from bispecific antibodies in FL & DLBCL, including how dosing schedules can meaningful impact time burden for patients & care partners. #lymsm news.cuanschutz.edu/cancer-cente...

Time Toxicity: Weighing the Benefits of Cancer Therapies Against Time Demands on Patients

A new study led by CU Anschutz Cancer Center member Ajay Major, MD, MBA, surveyed patients with relapsed lymphoma about the time burdens of treatments.

news.cuanschutz.edu

Speaking today at the IVI PCORI-funded Convening on time toxicity in patients with cancer. Excited to highlight our latest publication on measuring time toxicity as a patient-reported outcome: academic.oup.com/oncolo/artic... #lymsm #oncsky

5-year CLL13/GAIA follow-up: - 5-yr PFS: GIV 81%, GV 70%, RV 57%, CIT 51% - no OS differences - figure has uIGHV (B) vs mIGHV (C) - cardiac AEs highest with GIV - GV/RV had faster QoL improvements vs CIT; GIV QoL gains occurred later (more tx-related side effects) 1/

Super important data: PROs for R-pola-glo unfit 1L LBCL #lymsm - 80 pts, med age 80, 91% frail - high PRO completion >80% Despite frailty, clinically-meaningful QoL improvements: - global QoL during tx; 44% w/ sig improvement by C4 - physical function/fatigue maintained - emotional QoL improved 1/

RW epcor R/R LBCL outcomes (CUBIC Consortium): - 157 pts, 55% prior CAR, 46% trial ineligible - ORR 50%, CR 32% - mPFS 3.5 mo, mOS OS 7.6 mo - 1-year PFS 29%, 1-year OS 38% - ⬇️survival: poor PS,⬆️LDH, refractory, trial ineligible 1/ #lymsm pubmed.ncbi.nlm.nih.gov/42263668/

The latest findings from our ongoing BISON-PRO Quality of Life Study (bison-pro.org): measuring financial toxicity in patients with lymphoma & CLL from active surveillance through treatment and survivorship. Manuscripts forthcoming! #lymsm cc @cuhematology.bsky.social bison-pro.org/new-bison-pr...

New BISON-PRO Findings: Understanding Financial Stress in People with Lymphoma - BISON-PRO Quality of Life Study

We would like to share new findings from the BISON-PRO Quality of Life Study, focused on financial toxicity in people living with lymphoma and CLL.

bison-pro.org

Frontline H. pylori eradication for extragastric ENMZL #lymsm - 26 pts, 46% conjunctival, 19% parotid - ORR 65% (CR 39%, PR 27%), time to CR 6 mos - 7-yr EFS 77%, OS 96% - HP+ dx with better responses (obv), t(11;18) less responses Provocative evidence re: HP+ in non-gastric sites...

Fixed-duration SC mosun older/unfit 1L DLBCL #ASCO26 - median age 83 (71-101!), 53% IPI 3-5 - ORR 74%, CR 59% - 12-mo PFS 71%, OS 75% - CRS 12% (all G1-2), 49% infx (16% G3), 8% G5 AEs - PROs: 53% w/ improvements in lymphoma sx #lymsm

Hans IHC vs GEP for DLBCL COO classification #EHA2026 Large meta-analysis (19 studies, 2247 tumors) to eval noninferiority of Hans IHC to GEP. Estimated accuracy: - Hans IHC 90% - pooled GEP 95% - 4.5% difference met noninferiority margin - sens 6.5% / NPV 6.4% library.ehaweb.org/eha/2026/eha...

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) #lymsm #oncsky

Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL #lymsm - 120 pts actively receiving BsAb tx - fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco) - no difference in infusion time between IV and SQ academic.oup.com/oncolo/advan...

Congratulations to our Major Lab member Keegan Carroll on his abstract at @accordsresearch.bsky.social COPRH Con on patient-reported financial toxicity in patients with lymphoma. Look out for the future manuscript! #lymsm @cucancercenter.bsky.social @cuanschutz.bsky.social @cuhematology.bsky.social

Eager to be presenting at the @accordsresearch.bsky.social COPRH Con today on pragmatic use of PROs in cancer research! Joined by Drs. Sarah Tevis, Tyler Buckner, & Allison L'Hotta. #PRO #QoL cc @cuanschutz.bsky.social @cucancercenter.bsky.social @cuhematology.bsky.social

Prebiopsy steroids & diagnostic yield DLBCL #lymsm - 320 pts - yield unchanged w/ steroids (83% v 81%) - no association w/ dose/duration - no delay in time to treatment - FNA less diagnostic than excisional/incisional - core needle 12% less likely to be diagnostic jamanetwork.com/journals/jam...

Prebiopsy Steroids and Diagnostic Yield in Diffuse Large B-Cell Lymphoma

This cohort study evaluates whether corticosteroid use before biopsy is associated with the diagnostic yield in patients with newly diagnosed diffuse large B-cell lymphoma.

jamanetwork.com

ctDNA TRANSFORM #lymsm - MRDneg = longer EFS at all timepoints - more pts achieved MRDneg with liso-cel v SOC - among MRDneg pts liso-cel ⬆️ EFS, PFS, DOR - MRD re-emergence 1 yr: 0/20 liso-cel v 9/15 ASCT - ctDNA prognostic independent of PET Role for ctDNA+PET post-CAR? ascopubs.org/doi/pdf/10.1...